Raymond James & Associates Tekla Life Sciences Investors Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Tekla Life Sciences Investors stock. As of the latest transaction made, Raymond James & Associates holds 44,147 shares of HQL stock, worth $631,302. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,147
Previous 39,335
12.23%
Holding current value
$631,302
Previous $557,000
19.39%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding HQL
# of Institutions
75Shares Held
9.29MCall Options Held
0Put Options Held
0-
Saba Capital Management, L.P. New York, NY3.43MShares$49 Million1.1% of portfolio
-
Penserra Capital Management LLC Orinda, CA776KShares$11.1 Million0.25% of portfolio
-
Morgan Stanley New York, NY490KShares$7 Million0.0% of portfolio
-
Karpus Management, Inc. Pittsford, NY469KShares$6.7 Million0.23% of portfolio
-
Sit Investment Associates Inc Minneapolis, MN417KShares$5.96 Million0.14% of portfolio
About TEKLA LIFE SCIENCES INVESTORS
- Ticker HQL
- Exchange NYSE
- Sector Financial Services
- Industry Asset Management
- Description
- Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical...